Essential medicines selection

Trastuzumab (Addition) -- Adults

19th Expert Committee on the Selection and Use of Essential Medicines

Drug information

Section 8: Antineoplastic, immunosuppressives and medicines used in palliative care 8.2: Cytotoxic and adjuvant medicines

Formulation:

Trastuzumab 440 mg. Injection, powder + diluent for reconstitution, contains benzyl alcohol.

Application prepared by:
Union for International Cancer Control, Route de Frontenex, 62, 1207 Geneva, Switzerland and Dana-Farber Cancer Institute, Center for Global Cancer Medicine, 450 Brookline Avenue, Boston, MA 02215, USA

Formulation:

Powder for injection: 60 mg; 150 mg; 400 mg; 440 mg vials. Trastuzumab is used for the treatment of HER2 positive breast cancer.

Application prepared by:
Knowledge Ecology International, 1621 Connecticut Ave. NW, Suite 500, Washington, DC 20009, United States of America

University of California, San Francisco, Department of Medicine, 533 Parnassus Ave., Suite U112, San Francisco, CA 94143, United States of America

Universities Allied for Essential Medicines (UAEM) & Young, Professionals Chronic Disease Network (YP-CDN), Weill Cornell Medical College - The Rockefeller University -Sloan-Kettering Cancer Institute, 1230 York Avenue, Box 292, New York, NY 10065, United States of America

Proposal for the inclusion of trastuzumab in the WHO Model List of Essential Medicines for the treatment of HER2-positive breast cancer
pdf, 314kb

Comments from:

Letters of support from:

Share
Email Twitter Facebook Google Delicious LinkedIn
More...